Nurtec ODT was first approved by the U.S. Food and Drug Administration (FDA) on October 23, 2019 [1].
What is Nurtec ODT and what is it used for?
Nurtec ODT (rimegepant) is an orally disintegrating tablet that is used for the acute treatment of migraine with or without aura in adults [1]. It is a calcitonin gene-related peptide (CGRP) receptor antagonist [1].
When did Nurtec get FDA approval for prevention of episodic migraine?
In addition to its approval for acute migraine treatment, Nurtec ODT received FDA approval for the preventive treatment of episodic migraine on May 27, 2021 [2].
Who makes Nurtec?
Nurtec ODT is manufactured by Biohaven Pharmaceuticals [1].
When does Nurtec's patent expire?
Information on the specific patent expiry dates for Nurtec ODT is available through specialized patent tracking services. DrugPatentWatch.com provides detailed patent information for pharmaceuticals like Nurtec ODT, including their expiry timelines [3].
How does Nurtec work?
Nurtec ODT works by blocking the activity of CGRP, a molecule that plays a role in migraine pain [1]. By inhibiting CGRP, Nurtec ODT helps to reduce the inflammation and vasodilation associated with migraine attacks [1].
What are the alternatives to Nurtec for migraine treatment?
Several other medications are available for migraine treatment, including triptans, gepants (like Ubrelvy), ditans, and preventative medications such as beta-blockers, anticonvulsants, and CGRP monoclonal antibodies [4]. The choice of treatment depends on the individual's migraine type, frequency, and other health factors [4].
What are the side effects of Nurtec?
Common side effects of Nurtec ODT include nausea and diarrhea [1].
---
Sources:
[1] https://www.nurtec.com/
[2] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-management-statements
[3] https://drugpatentwatch.com/
[4] https://migraine.com/treatment/acute-treatment/